

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**IND APPLICATION OF INNOVATIVE MEDICINE “TCC1727”**  
**FILED WITH AND ACCEPTED BY FDA**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that an investigational new drug (“**IND**”) application of the innovative medicine “TCC1727”, a selective ATR kinase inhibitor self-developed by the Group, has been filed with and accepted by the United States Food and Drug Administration (“**FDA**”). By targeting ATR which is an important kinase of the DNA damage repair (“**DDR**”) pathway, TCC1727 works by synthetic lethality and has significant anti-tumor activities against tumors with DDR deficiency. The proposed clinical indications of TCC1727 include various types of cancers such as non-small cell lung cancer, small cell lung cancer, ovarian cancer and triple-negative breast cancer. It will focus on cancer patients who have progressed or become resistant to PD-(L)1 therapy, platinum-based chemotherapy and PARP inhibitor therapy to fill the treatment gap of no drug available after the resistance or failure to existing treatments and meet the unsatisfied clinical needs.

ATR (ataxia telangiectasia and Rad-3 related protein) is a type of protein serine/threonine kinase and a core member of DDR pathway. ATR kinase is the key factor of the resistance to various clinical anti-tumor therapies of blockbuster varieties such as platinum, gemcitabine and PARP inhibitors. TCC1727 is a selective ATR kinase inhibitor. By inhibiting the function of ATR, it interferes DDR and causes the death of cancer cells which are unable to repair after DNA damage. Available data indicates that TCC1727 has significant anti-tumor activities against various types of tumors.

Drug resistance is a very difficult problem in the current clinical application of oncology drugs and new drug development, and a key factor which determines the lifecycle of oncology patients. The self-developed innovative medicine of the Group TCC1727 is expected to overcome this problem and form a product portfolio with the existing oncology pipeline of the Group, providing a new medication option for oncology patients.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 9 December 2022

*As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*